Finance Business Partner for Global Procurement at GSK with direct reports in UK, Belgium and Poland - Partnered with the Global Procurement leadership team to enhance the Procurement P&L impacting savings delivery vs Plan targeting the highest P&L savings delivery yet.- Secured funding for the Procurement digital transformation initiative by developing a comprehensive financial business case that was approved by the GSK CFO.- Reduced inflation volatility vs Plan by developing a risk management policy and implementing a governance to forward buy energy and selected commodities

Finance integration lead with project team, line manager of the Affinivax Finance team. - Implemented the new GSK Finance operating model and reduced local Finance headcount at Affinivax by transferring existing on-site Finance processes to the central GSK Finance organization. - Developed the Finance integration plan by defining milestones and identifying potential interdependencies with other functional workstreams. Secured approval from Steering Committee.- Successfully delivered ERP Go Live by defining and executing a detailed cutover plan. - Ensured effective change management by conducting on-site Super User trainings and frequent engagement with the local team on new Finance processes via different channels.

Global Finance Business Partner for Capital Expenditures, global functions for Quality & Manufacturing and Value Creation at Vaccines with direct reports in Belgium and UK. Secretary of the Network Investment Board of GSK. - Secured funding of a major investment in Belgium Operations by developing a comprehensive financial business case including GSK Board paper. Secured endorsement of more than 10 large investments by developing the business case including CEO/ CFO paper.- Led a vaccines product review for GSK: Developed long-term financials, prepared financials for the data room and contributed to negotiations with potential investors.- Partnered with the business to deliver Future Ready plans including milestones for global Quality and global Manufacturing functions resulting in material savings vs Plan.- Enhanced the Value Creation process for Vaccines by collaborating with the sites to ensure better alignment with the Plan, reconciliation with the P&L and extending the Value Creation pipeline to a three-year period.

Regional Finance lead for all GSK Vaccines Secondary manufacturing sites with local Finance teams in Canada, China, France, Germany, Italy, Russia and USA.- Developed comprehensive financial scenarios for our manufacturing facilities in Hangzhou, Shanghai and Moscow which triggered the decision to divest and/ or close the sites.- Successfully implemented the new Finance operating model at the Rosia site in Italy by transferring existing on-site Finance processes to the central GSK Finance organization.- Partnered with the business to implement productivity improvements at the Rosia site which resulted in a material reduction of the workforce within 3 years.

- Led transition to new GSK operating model for Finance and Procurement on site.

Finance lead for all finance related matters of the legal entity including Purchasing and IT with 50+ employees. Managing Director of the legal entity. Member of the Novartis Vaccines Finance Leadership team.- Carved out the existing Flu business into a new entity in preparation of the announced acquisition by GSK.

Finance lead for all finance related matters of the legal entity including indirect Purchasing and IT with around 50+ employees. Managing Director of the legal entity.